Ninety-five patient groups are pushing for CVS Caremark to roll back its recent decision to let clients scrap coverage for high-cost drugs based on a cost-effectiveness threshold aligned with assessments from the Institute for Clinical and Economic Review, the Washington Examiner reports.
The PBM’s policy would have focused on treatments exceeding the $100,000 price mark.
According to the report, the groups, including the Vietnam Veterans of America and the Alliance for Aging Research, say the assessment reports “ignore important differences among patients” and lean on a one-size-fits-all model.
“Cost-effectiveness analysis discriminates against the chronically ill, the elderly and people with disabilities, using algorithms that calculate their lives as ‘worth less’ than people who are younger or non-disabled,” the groups reportedly wrote to CVS.
Click here to read the full report on the Washington Examiner.
